Azacitidine

Metastatic Melanoma

M.D. Anderson Cancer CenterSmall moleculePhase 2Dormant

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 47/ 100
Competitive Position: 73/ 100

Competitive context

104 Active assets in the Metastatic Melanoma cohort.

Asset / Sponsor	Phase	Rating
Cediranib M.D. Anderson Cancer Center	Phase 2	BBB
DACARBAZINE Shanghai Junshi Bioscience Co., Ltd.	Phase 4	BBB
Ifa Craig L Slingluff, Jr	Phase 2	BB
Nivolumab Bristol-Myers Squibb	Phase 4	BB
Therapeutic Autologous Lymphocytes Fred Hutchinson Cancer Center	Phase 2	BB

View all 50 →

Same molecule, other indications

Azacitidine is also rated in:

acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant

BBB

Indicative ·

73 / 100

acute erythroid leukemiaDormant

BB

Indicative ·

71 / 100

non-small cell lung carcinomaDormant

BB

Indicative ·

71 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.